Neoplasms, Nerve Tissue clinical trials
The registry lists 22 studies for Neoplasms, Nerve Tissue across more than 10 countries. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-10-16. Counting its 44 narrower conditions too, such as Melanoma: 9,340 studies, 1,986 open.
Get an email when these change. Save the Neoplasms, Nerve Tissue studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
NaviFUS Corporation (4) · Blueprint Medicines Corporation (3) · Hoffmann-La Roche (2) · DNAtrix, Inc. (2) · Ludwig-Maximilians - University of Munich (1) · National Cancer Institute (NCI) (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Assistance Publique - Hôpitaux de Paris (1)
What is being tested here
Drugs under test in Neoplasms, Nerve Tissue studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| LMP-744 | 1 | 0 | 1 |
| G 207 | 1 | 0 | 1 |
| Oncolytic HSV-1 G207 | 1 | 0 | 1 |
| Contrast agent BR1 | 1 | 1 | 1 |
| Sulfur Hexafluoride | 1 | 1 | 1 |
| Bevacizumab | 0 | 0 | 2 |
| Pralsetinib | 0 | 1 | 2 |
| Tasadenoturev | 0 | 0 | 1 |
| Oncolytic Virus | 0 | 0 | 1 |
| Sunitinib | 0 | 0 | 1 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 5 · Angiogenesis inhibitors 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 4 Neoplasms, Nerve Tissue studies recruiting now, 0 (0%) set no upper age limit and 1 (25%) stop at 75 or younger. 1 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (25%) | 1 (25%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 3 (75%) | 3 (75%) |
| 40 | 3 (75%) | 3 (75%) |
| 50 | 3 (75%) | 3 (75%) |
| 65 | 3 (75%) | 3 (75%) |
| 75 | 3 (75%) | 3 (75%) |
| 85 | 2 (50%) | 2 (50%) |
Across all 22 studies, recruiting or not: 18% stop at 75 or younger and 9% at 65; 18% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 22 of 22. search them.
- Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaRecruitingNCT07416188Phase 1/21 country
- HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsRecruitingNCT03911388Phase 11 country
- A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme PatientsRecruitingNCT06496971Phase 31 country
- Spanish Series of Patients Treated With the Radionuclide Lutetium177RecruitingNCT049492821 country
- Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)SuspendedNCT06329570Phase 1/21 country
- Vorasidenib Expanded Access ProgramApproved for marketingNCT05592743
- Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM PatientsCompletedNCT04446416Not applicable1 country
- A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04222972Phase 322 countries
- Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompletedNCT03037385Phase 1/213 countries
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCTerminatedNCT04862780Phase 110 countries
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLCTerminatedNCT05153408Phase 11 country
- External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLCStatus unknownNCT046974463 countries
- Combination Adenovirus + Pembrolizumab to Trigger Immune Virus EffectsCompletedNCT02798406Phase 22 countries
- Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.Status unknownNCT04388033Phase 1/21 country
- Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) PatientsCompletedNCT03626896Not applicable1 country
- Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)WithdrawnNCT03109301Phase 2
- DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain TumorsCompletedNCT02197169Phase 11 country
- A Combined Cell Therapy Approach to the Treatment of NeuroblastomaWithdrawnNCT02745756Phase 1
- Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid TumorsCompletedNCT01177007Phase 21 country
- Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine TumorsTerminatedNCT01215578Phase 21 country
- A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)CompletedNCT00753415Phase 1
- Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma PatientsStatus unknownNCT015792531 country